Today,
Resolution on Directed New Share Issue for the Creation of Equalization Shares (Item 6)
The Extraordinary General Meeting resolved through a directed new B share issue, increase the company's share capital by a maximum of
The right to subscribe for the new B-shares shall belong to
Resolution on Amendment of the Articles of Association (Item 7)
The Extraordinary General Meeting resolved on an amendment of the Articles of Association in accordance with the following:
*Please note that the changes only apply for the Swedish version of the Articles of Association.
Current Wording | Proposed Wording |
§ 4 Aktiekapital Aktiekapitalet skall utgöra lägst 15 000 000 kronor och högst 60 000 000 kronor.
| § 4 Aktiekapital Aktiekapitalet skall utgöra lägst 18 000 000 kronor och högst 72 000 000 kronor.
|
§ 5 Antal aktier Antalet aktier skall vara lägst 700 000 000 och högst 2 800 000 000 stycken.
| § 5 Antal aktier Antalet aktier skall vara lägst 7 800 000 och högst 31 200 000 stycken.
|
Resolution on Consolidation of Shares (Item 8)
The Extraordinary General Meeting resolved, with the aim of achieving a more efficient number of shares for the company, to consolidate shares in a ratio of 200:1, meaning that 200 shares will be consolidated into 1 share. The Board is proposed to be authorized, until the fifth business day before the next Annual General Meeting at the latest, to determine the record date when the consolidation shall be executed and to take the other measures required to implement the consolidation.
The Decision entails that the company's share capital, after a decision on equalization share issue and consolidation, amounts to 18 134 146,882
Further information regarding the process of consolidation of the shares will be presented in a separated PM when the decisions above has been registered at the Swedish Companies Registration Office.
For more information, please contact:
Dan J Mogren, CEO,
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
Website: www.clinicallaser.se
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
The information was submitted for publication through the agency of the contact person stated above on
About CLS
For more information about CLS, please visit the Company's website: www.clinicallaser.se
https://news.cision.com/cls/r/bulletin-from-the-extraordinary-general-meeting-on-friday-12th-of-april-in-clinical-laserthermia-sys,c3961098
https://mb.cision.com/Main/11591/3961098/2729733.pdf
(c) 2024 Cision. All rights reserved., source